The consumer goods behemoth Procter & Gamble is undergoing a significant and extensive reshuffling of its senior leadership team. This period of change, occurring as the company contends with fierce competition and eroding market share, has cast a spotlight on near-term operational stability. The latest development involves the planned departure of Jennifer Davis, the head of the critical Health Care division, announced just weeks before a scheduled change at the very top of the corporation.
A Wave of Executive Changes
Jennifer Davis, a 33-year company veteran who has led the Health Care segment since 2022, will retire on June 30, 2026. Her division, home to powerhouse brands such as Oral-B, Vicks, and Crest, is a substantial contributor to P&G’s bottom line, accounting for approximately 14% of the group’s total annual revenue of $84 billion in fiscal 2025. A successor for this pivotal role has not yet been named, adding a layer of uncertainty to an already fluid situation.
This exit is not an isolated event but part of a broader management overhaul. In a matter of weeks, on January 1, 2026, Shailesh Jejurikar is set to assume the role of Chief Executive Officer from Jon Moeller. Furthermore, it was revealed last summer that Alexandra Keith, CEO of the global Beauty business, will also step down in early 2026. Market observers interpret this series of moves as a deliberate generational shift. The incoming CEO, Jejurikar, will face the immediate challenge of maintaining business continuity amidst this leadership flux.
Market Share Pressures Overshadow Earnings Beat
Despite Procter & Gamble reporting first-quarter earnings that surpassed expectations and reaffirming its fiscal 2026 outlook, a note of caution has dominated recent analyst commentary. Major financial institutions, including Deutsche Bank, Wells Fargo, and UBS, have moved to lower their price targets for the company’s shares.
Should investors sell immediately? Or is it worth buying Procter & Gamble?
This analyst skepticism stems from tangible operational headwinds. The firm has recently ceded global market share, losing 30 basis points, as rivals in core markets like North America and Europe wage aggressive discounting campaigns. Sectors such as fabric care and baby products are feeling particular competitive strain. In response, P&G has initiated a restructuring program that could affect up to 7,000 positions.
The stock’s performance reflects this persistent investor concern. Although shares managed to advance in the latest trading session, they remain down roughly 23% since the start of the year. The current price of €123.58 sits well below the 52-week high.
A Pivotal Period Ahead
The coming months will be critical for investor confidence. All eyes will be on Shailesh Jejurikar as he formally takes the helm on January 1, 2026, with the new leadership team under pressure to demonstrate a strategy to halt market share declines. Additionally, the markets await two key announcements: the appointment of a new head for the Health Care segment and the next set of quarterly results, due in late January.
Ad
Procter & Gamble Stock: Buy or Sell?! New Procter & Gamble Analysis from December 16 delivers the answer:
The latest Procter & Gamble figures speak for themselves: Urgent action needed for Procter & Gamble investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from December 16.
Procter & Gamble: Buy or sell? Read more here...
